

3/6/2017

## Conflict of Interest Disclosures BLOOD

<b>00000428364</b>	<b>Herve Avet Loiseau, MD, PhD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date:</b>
--------------------	------------------------------------	-------------------------	-----------------------------

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
Janssen-Cilag	Membership on a Board or Advisory Committee		

<b>000000123461</b>	<b>Nancy Berliner, MD</b>	<b>Deputy Editor</b>	<b>Last Confirmed Date: 01/24/2017</b>
---------------------	---------------------------	----------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
Clinical Decision Support	Patents & Royalties	On-line clinical support text; currently an Associate Editor. Program is in development. We have receivedn No royalties to date.	
Novartis	Research Funding	Research funding for preclinical and clinical trials transferred to me as PI upon the departure of one of our junior faculty.	01/01/2034
Up To Date	Honoraria	Author for UpToDate. Receive honoraria for updating chapters.	

<b>000000124002</b>	<b>David M. Bodine, PhD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/27/2017</b>
---------------------	-----------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Nothing to disclose.		

<b>000000427017</b>	<b>Catherine M. Bollard, MD, FRACP, FRCPA</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/27/2017</b>
---------------------	---	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Nothing to disclose.		

## Conflict of Interest Disclosures BLOOD

<b>00000127066</b>	<b>John C. Byrd, MD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/26/2017</b>
--------------------	-------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		05/04/2015
Acerta	Consultancy	Unpaid Consultant	12/31/2017
Boehringer-Ingelheim	Consultancy	Unpaid consultant	12/31/2017
Emergent Biotech	Consultancy	Unpaid consultant	12/31/2016
Genentech	Consultancy	Unpaid consultant	12/31/2017
Gilead	Consultancy	Unpaid consultant	12/31/2017
Immunomedics	Consultancy	Unpaid consultant	12/31/2015
Janssen/J&J	Consultancy	Unpaid Consultant	12/31/2016
Pharmacyclics	Consultancy	Unpaid consultant	12/31/2016

<b>00000123418</b>	<b>Mario Cazzola, MD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/28/2017</b>
--------------------	--------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		
Incyte Corporation	Membership on a Board or Advisory Committee		

## Conflict of Interest Disclosures BLOOD

000000122721	Thomas D. Coates, MD	Associate Editor	Last Confirmed Date: 08/03/2016
Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		07/17/2015
Agios Pharma	Consultancy		01/01/2018
Apo Pharma	Consultancy	have consulted on content of presentations regarding iron chelation	01/01/2016
Apo Pharma	Speakers Bureau	have spoken RE use of iron chelators	01/01/2016
Celgene	Consultancy	have done advisory board in past	01/01/2019
Novartis Pharma	Consultancy	have consulted RE content of presentations on hemoglobinopathies	01/01/2016
Novartis Pharma	Speakers Bureau	speak on use of chelators	01/01/2016
Prolong PHarma	Consultancy	consult regarding treatment of sickle cell disease	01/01/2018
UpToDate	Patents & Royalties	Receive royalties for chapters written for Up To Date	01/01/2018

## Conflict of Interest Disclosures

### BLOOD

000000127023	Jorge Cortes, MD	Associate Editor	Last Confirmed Date: 01/28/2017
Company:	Relationship:	Additional Information	End Date
	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2015
	Research Funding	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2015
Ariad	Research Funding		
Ambit	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2015
Ambit Biosciences	Research Funding		
Ariad	Consultancy	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Ariad	Research Funding		
ARIAD	Research Funding		
Ariad	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Astellas	Consultancy	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2015
Astellas	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2015
Biopath Holdings	Consultancy		12/31/2017
BMS	Consultancy	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017

## Conflict of Interest Disclosures

### BLOOD

BMS	Research Funding	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
BMS	Research Funding	Research Funding	
Bristol-Myers Squibb	Research Funding		
ChemGenex	Membership on a Board or Advisory Group		
ChemGenex	Research Funding		
Chemgenix	Research Funding		
Imunogen	Consultancy		12/31/2017
Imunogen	Research Funding	Date is estimated, depends on end of trial and may be extended for completion of this and/or start of other trials.	12/31/2017
Jazz	Consultancy		12/31/2017
Jazz	Research Funding	Support to my institution for ongoing trials; may be extended depending on completion of this trial and start of new ones.	12/31/2017
Novartis	Consultancy	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Novartis	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Novartis	Research Funding	Research Funding	
Pfizer	Consultancy	Ongoing on an ad hoc basis. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Pfizer	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Targegen	Research Funding		

## Conflict of Interest Disclosures BLOOD

Teva	Research Funding	Funding to my institution for clinical trials. Might be extended beyond the stated date upon agreement from both parties.	12/31/2017
Wyeth	Research Funding	Research Funding	

00000428020	David Garcia, MD	Special Section Editor	Last Confirmed Date: 02/08/2017
Company:	Relationship:	Additional Information	End Date
Alexion	Consultancy		10/01/2015
Boehringer Ingelheim	Consultancy		02/01/2016
Bristol Meyers Squibb	Consultancy	Expert retained by attorneys representing BMS in multi-district litigation involving apixaban.	01/01/2018
Daiichi Sankyo	Research Funding	I am the US National Coordinator for a clinical trial (sponsored by this company) that will compare edoxaban to LMWH for the treatment of cancer-associated venous thromboembolism	01/01/2018
Genzyme	Consultancy		05/30/2015
Incyte	Consultancy		10/01/2015
Incyte	Research Funding		01/01/2017
Janssen	Consultancy		01/01/2018
Janssen	Research Funding	I will serve on the steering committee for a trial sponsored by Janssen that will evaluate rivaroxaban for the primary prevention of venous thrombosis in patients with pancreatic cancer.	01/01/2017
Pfizer	Consultancy	I have served as a consultant to this company.	07/01/2016
Portola	Research Funding	I will serve on the data safety monitoring board of a clinical trial sponsored by this Portola.	01/01/2016

## Conflict of Interest Disclosures BLOOD

<b>00000424542</b>	<b>Margaret A. Goodell, PhD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/29/2017</b>
--------------------	---------------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
-----------------	----------------------	-------------------------------	-----------------

Nothing to disclose.

<b>00000126615</b>	<b>Jose A. Lopez, MD, BS</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/27/2017</b>
--------------------	------------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
-----------------	----------------------	-------------------------------	-----------------

Nothing to disclose.

## Conflict of Interest Disclosures

### BLOOD

000000121045	Bob Lowenberg, MD, PhD	Editor	Last Confirmed Date: 01/25/2017
Company:	Relationship:	Additional Information	End Date
“Up-to-Date”, section editor leukemia	Membership on a Board or Advisory Committee	End date undetermined	
Astex	Consultancy	Data Safety Monitoring Board	12/31/2018
Celgene	Consultancy		03/31/2015
Chairman Scientific Committee and Member Executive Committee, European School of Hematology (ESH, Paris, France)	Membership on a Board or Advisory Committee		01/01/2019
Chairman, Leukemia Cooperative Trial Group HOVON (Netherlands)	Membership on a Board or Advisory Committee		01/01/2018
Editorial Board “European Oncology & Haematology”	Membership on a Board or Advisory Committee	End date undetermined	
Editorial Board “International Journal of Hematology”	Membership on a Board or Advisory Committee	End date undetermined	
Editorial Board “The Netherlands Journal of Medicine”	Membership on a Board or Advisory Committee	End date undetermined	
Elected member, Royal Academy of Sciences and Arts, The Netherlands	Membership on a Board or Advisory Committee	No end date, permanent membership	
Erasmus University Medical Center/Bob Löwenberg	Patents & Royalties	Patents 1. Diagnostic classification of AML including the use analytical software and visualization of the data (patent number: EP 4075570) 2. Knowledge about novel evolutionary conserved leukemia-relevant pathways between mice and humans (patent number PCT/NL2006/00273) 3. MicroRNA-9/9* as an attractive target for the therapy of acute myeloid leukemia. (patent number EP 2243833)	
international Scientific Advisory Board, Institute Gustave Roussy, Paris	Membership on a Board or Advisory Committee		01/01/2016
Permanent Member of the Netherlands Health Council	Membership on a Board or Advisory Committee		
Royal Academy of Sciences and Arts, The Netherlands	Membership on a Board or Advisory Committee		01/01/2037



## Conflict of Interest Disclosures BLOOD

Supervisory Board, National Comprehensive Cancer Center (IKNL), Netherlands	Membership on a Board or Advisory Committee	01/01/2018
---	---	------------

00000126102	Thomas L. Ortel, MD, PhD	Associate Editor	Last Confirmed Date: 02/10/2017
<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Membership on a Board or Advisory Committee	American Board of Internal Medicine Hematology Test Question Committee	06/30/2016
	Nothing to disclose.		07/13/2016
American Board of Internal Medicine	Membership on a Board or Advisory Committee	Hematology Test Writing Committee.	06/30/2016
BMS-Squibb	Honoraria	Speaker at a VTE Advocacy Meeting	05/01/2016
Instrumentation Laboratory	Consultancy	Provide recommendations concerning hemostasis testing.	01/01/2020
Instrumentation Laboratory	Research Funding	Research support	01/01/2020
Siemens	Research Funding		
Up To Date	Membership on a Board or Advisory Committee	Write sections on anticoagulant therapy in patients with infectious endocarditis and diagnosis and treatment of antiphospholipid syndrome.	01/01/2036

00000123353	Leslie V. Parise, PhD	Associate Editor	Last Confirmed Date: 02/05/2017
<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
Oklahoma Medical Research Foundation	Consultancy	Attend yearly Scientific Advisory board meeting and make recommendations	01/01/2018
Oklahoma Medical Research Foundation	Honoraria	Attend yearly Scientific Advisory board meeting and make recommendations	01/01/2018
Oklahoma Medical Research Foundation	Membership on a Board or Advisory Committee	Attend yearly Scientific Advisory board meeting and make recommendations	01/01/2018

## Conflict of Interest Disclosures BLOOD

<b>000000122110</b>	<b>Jacob M. Rowe, MB, BS</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 02/09/2017</b>
---------------------	------------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
Amgen	Consultancy		01/01/2016
BioLineRx	Membership on a Board or Advisory Committee		
ImmunPharm	Membership on a Board or Advisory Committee		
Kyowa Kirin	Membership on a Board or Advisory Committee		
Orsenix	Membership on a Board or Advisory Committee		
Teva Pharmaceuticals	Consultancy		01/01/2016

## Conflict of Interest Disclosures BLOOD

<b>00001000431</b>	<b>Laurie Sehn, MD, MPH</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/25/2017</b>
--------------------	-----------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Consultancy		01/01/2016
	Consultancy		01/01/2037
	Honoraria		01/01/2037
	Honoraria		01/01/2037
"Roche, Inc"	Research Funding		
"Roche, Inc."	Consultancy		
Abbvie	Consultancy		01/01/2016
Amgen	Consultancy		01/01/2016
Celgene	Consultancy		01/01/2016
Genentech	Honoraria		
Gilead	Consultancy		01/01/2016
Janssen	Consultancy		01/01/2016
Lundbeck	Consultancy		01/01/2016
Ortho Biotech	Honoraria		
Ortho-Biotec	Honoraria		
Roche	Consultancy		
Roche	Honoraria	Honoraria	
Roche	Membership on a Board or Advisory Committee		
Roche	Research Funding		
Roche, Genentech	Honoraria		01/01/2037
Roche/Genentech	Consultancy		01/01/2016
Seattle Genetics	Equity Ownership		
TG Therapeutics	Consultancy		01/01/2016

<b>00001003876</b>	<b>Jean Soulier, MD, PhD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/28/2017</b>
--------------------	------------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Research Funding	Effimune	12/31/2016
Effimune	Research Funding		12/31/2016

## Conflict of Interest Disclosures BLOOD

<b>000001089568</b>	<b>Freda K. Stevenson, DPhil</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 12/10/2016</b>
---------------------	----------------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Nothing to disclose.		

<b>000000123573</b>	<b>Georgia B. Vogelsang, MD</b>	<b>Special Section Editor</b>	<b>Last Confirmed Date: 01/27/2017</b>
---------------------	---------------------------------	-------------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Nothing to disclose.		01/27/2017
Pharmacyclics	Consultancy	Independent Response Review Committee	12/30/2016

<b>000001005668</b>	<b>Robert Zeiser, MD</b>	<b>Associate Editor</b>	<b>Last Confirmed Date: 01/28/2017</b>
---------------------	--------------------------	-------------------------	--

<b>Company:</b>	<b>Relationship:</b>	<b>Additional Information</b>	<b>End Date</b>
	Nothing to disclose.		